Press release
Advanced Hepatocellular Carcinoma Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Advanced Hepatocellular Carcinoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/advanced-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report
* In August 2025, Bristol-Myers Squibb announced a study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).
* In August 2025, Coherus Biosciences Inc . conducted a Phase 2 trial composed of an open label Lead-In followed by a Randomized Phase designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo (inactive substance) in combination with atezolizumab plus bevacizumab in patients with first-line advanced or metastatic HCC.
* In August 2025, AstraZeneca organized a study is to assess the efficacy and tolerability of rilvegostomig in combination with bevacizumab with or without tremelimumab as first-line treatment in participants with advanced HCC. The study comprises 2 parts - a safety lead-in and a randomised period. Prior to the start of the randomised period of the study, a single-arm safety lead-in period will be applied to evaluate the safety and tolerability of rilvegostomig in combination with bevacizumab and tremelimumab.
* DelveInsight's Advanced Hepatocellular Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Hepatocellular Carcinoma treatment.
* The leading Advanced Hepatocellular Carcinoma Companies such as CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics and others.
* Promising Advanced Hepatocellular Carcinoma Pipeline Therapies such as ADI-PEG20, Tegavivint, Lenvatinib, Cabozantinib, Durvalumab, Tremelimumab, SHR-8068, Adebrelimab, Bevacizumab, Lenvatinib, Nivolumab, Enzalutamide and others.
Learn how leading Advanced Hepatocellular Carcinoma Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ Advanced Hepatocellular Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/advanced-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Advanced Hepatocellular Carcinoma Emerging Drugs Profile
* Tivozanib : AVEO Oncology
FOTIVDA Registered (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models. Currently, Tivozanib is being evaluated in Phase I/II stage of clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.
* Nofazinlimab: CStone Pharmaceuticals
CS1003 is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed for immunotherapy of various tumors. Compared to most of the monoclonal antibodies that bind human and monkey PD-1(either already approved or in clinical stage) , CS1003 demonstrates comparable high binding affinities across species against human, cynomolgus monkey and mouse PD-1, and is developed to disrupt the interaction of PD-1 with its ligands PD-L1 and PD-L2 . CS1003 is also unique in that it can simultaneously recognize human and mouse PD-1, which allows fast pre-clinical proof of concept for CS1003 in combination with novel targeted therapies using syngeneic mouse tumor models. Currently, the drug is being developed in Phase III stage of development for the treatment of advanced hepatocellular carcinoma.
* ECT 204: Eureka Therapeutics
ECT204, a GPC3 targeting ARTEMIS Registered T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer. Glypican 3 (GPC3) is a promising target for HCC therapies and is found in more than 70% of HCC cells. The GPC3 protein is also expressed in other solid tumors including ovarian and lung cancer. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.
* Sintilimab: Eli Lilly and Company/Innovent
Sintilimab is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies of sintilimab worldwide, to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials. Sintilimab, marketed as TYVYT Registered (sintilimab injection) in China, is an innovative PD-1 inhibitor with global quality standards jointly developed by Innovent and Eli Lilly and Company. Currently, the drug is being developed in Phase I stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.
The Advanced Hepatocellular Carcinoma Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Hepatocellular Carcinoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Hepatocellular Carcinoma Treatment.
* Advanced Hepatocellular Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Advanced Hepatocellular Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Hepatocellular Carcinoma market.
From early-stage research to late-phase Advanced Hepatocellular Carcinoma Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ Advanced Hepatocellular Carcinoma Treatment Drugs [https://www.delveinsight.com/sample-request/advanced-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Advanced Hepatocellular Carcinoma Companies
CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics and others.
Advanced Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Advanced Hepatocellular Carcinoma Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Stay updated with the latest Advanced Hepatocellular Carcinoma Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ Advanced Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/advanced-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Advanced Hepatocellular Carcinoma Pipeline Report
* Coverage- Global
* Advanced Hepatocellular Carcinoma Companies- CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics and others.
* Advanced Hepatocellular Carcinoma Pipeline Therapies- ADI-PEG20, Tegavivint, Lenvatinib, Cabozantinib, Durvalumab, Tremelimumab, SHR-8068, Adebrelimab, Bevacizumab, Lenvatinib, Nivolumab, Enzalutamide and others.
* Advanced Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Advanced Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest Advanced Hepatocellular Carcinoma Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Advanced Hepatocellular Carcinoma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/advanced-hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Advanced Hepatocellular Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Advanced Hepatocellular Carcinoma- DelveInsight's Analytical Perspective
* Late Stage Products (Pre-Registration)
* Drug name : Company Name
* Last Stage Products (Phase III)
* Nofazinlimab: CStone Pharmaceuticals
* Mid Stage Products (Phase I/II)
* Tivozanib : AVEO Oncology
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Advanced Hepatocellular Carcinoma Key Companies
* Advanced Hepatocellular Carcinoma Key Products
* Advanced Hepatocellular Carcinoma - Unmet Needs
* Advanced Hepatocellular Carcinoma - Market Drivers and Barriers
* Advanced Hepatocellular Carcinoma - Future Perspectives and Conclusion
* Advanced Hepatocellular Carcinoma Analyst Views
* Advanced Hepatocellular Carcinoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-hepatocellular-carcinoma-pipeline-outlook-report-2025-key-50-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/advanced-hepatocellular-carcinoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Hepatocellular Carcinoma Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4142777 • Views: …
More Releases from ABNewswire
Best Delhi Astrologer in Paschim Vihar Offers Trusted Guidance and Astrological …
Astrology remains a powerful tool for navigating life's complexities, and the Best Delhi Astrologer in Paschim Vihar has proven to be a guiding force for countless individuals. With a blend of tradition, experience, and personalized attention, this Delhi astrologer continues to earn trust and respect. For those searching for the best astrologer in Delhi or a famous astrologer in Delhi, the guidance offered from Paschim Vihar has become a dependable…
Dr. Anil Shah Launches Powerful Retinol Formula to Improve Post-Rhinoplasty Heal …
New York, NY & Chicago, IL - Dr. Anil Shah, a double board-certified facial plastic surgeon with practices in New York City and Chicago, has unveiled a breakthrough in post-surgical skincare: a 1.5% time-released retinol developed specifically for rhinoplasty patients. This product, part of his Aesthetic Skin line, is designed to help patients achieve smoother, more refined results after nasal surgery while restoring skin health.
One of the most common concerns…
Moroccan Digital Agency RHILLANE Expands to Gulf Markets Following Industry Reco …
Tangier, Morocco - September 12, 2025 - RHILLANE Marketing Digital announced plans to open offices in the UAE, Kuwait, and Qatar by the end of September, following recognition as a top-rated digital marketing agency on industry platforms Sortlist and Clutch this month.
The Tangier-based agency, which has generated over $240 million in client sales, cited overwhelming demand from Gulf businesses seeking performance-guaranteed digital marketing services as the driver behind the expansion.
"We're…
Civil Engineering Outsourcing by IBN Technologies Transforms Project Delivery fo …
Civil engineering outsourcing is transforming how construction and infrastructure firms manage planning, design, and compliance. As projects grow in complexity, businesses are adopting outsourced models to reduce costs, accelerate delivery, and strengthen quality standards. The shift highlights a broader move toward digital collaboration and specialized expertise driving consistent outcomes in global construction.
Miami, Florida - 12 Sep, 2025 - The construction and infrastructure sector is undergoing a transformation as firms seek…
More Releases for Advanced
Advanced Oxidation Technologies Market Size, Share 2021, Impressive Industry Gro …
The Advanced Oxidation Technologies Market is poised to take off in upcoming years hence showing a highly positive outlook through 2020-2028, according to a recently released report. Advanced Oxidation Technologies Market report covers industry chain analysis, latest market trends & dynamics along with cost profit analysis of major key players which focuses on expansion rate, prices, competition, size, prices, and value chain analysis of those leaders in the market.
The…
Medical Ceramics Market Analysis and Industry Forecast | Advanced Ceramics Resea …
Allied Market Research published a new report, titled, “Medical Ceramics Market by Type (Aluminum Oxide, Zirconia, and Carbon, Hydroxyapatite, Glass & Bioglass, Zirconia Alumina, Bioresorbable Ceramics, and Piezo Ceramics), by Application (Surgical Instruments, Diagnostic Equipment, Orthopedic Implants, Electronic Implants, Dental Implants, Disposables, and Packaging) – Global Opportunity Analysis and Industry Forecast, 2014 – 2022.” The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter’s Five…
Skincell Advanced Reviews – Does Skincell Advanced Really Work?
People want clear, blemish-free skin! However, most people have skin tags, moles, and warts. Some causes are known, while some blemishes are caused without any reason at all. When a regular skincare regimen fails, people turn to costly surgeries and medications. Cleansing and moisturizing might not work well for all. All skin types are not the same, and toners and skincare creams seldom give long-lasting benefits.
Get Skincell Advanced From Its…
Global Advanced Oxidation Technologies Market 2019- 2025 || A-Zone Technologies, …
Synopsis of the Advanced Oxidation Technologies Market:
Latest Report on Advanced Oxidation Technologies Market deliberates the effect of various Factors influencing the market growth and drivers. Its further sheds light on market overview, key manufacturers, strategic adopted by them, size, latest trends and types, revenue, gross margin with regional analysis and forecast to 2025.
Overview of the Advanced Oxidation Technologies Market Report:
Advanced Oxidation Technologies Market report includes knowledge about the market overview…
Global Advanced Materials Market - 3M Company, DowDuPont Inc, Hexcel Corporation …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market - By Product type (Structural Material, Functional Material, Emerging Material) By End User (Building & Construction, Automotive, Aerospace, Defense, Marine, Electrical & Electronics, Healthcare, Oil & Gas and Energy, Others) & Global Region - Market Size, Trends, Share and Forecast 2018-2023” research report will include all the major trends and technologies that…
Global Advanced Materials Market: 3M Company, DowDuPont Inc, Hexcel Corporation, …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market 2017: Market Size, Trends & Opportunity Outlook – Forecast to 2023” research report will include all the major trends and technologies that play an important role in market growth in the predicted span of 6 years. It also presents the overview of industry players, advantages, challenges the business is going through. The…
